Skip to main content

Table 1 Subject characteristics of RA patients and control in 2011

From: Change in dietary inflammatory index score is associated with control of long-term rheumatoid arthritis disease activity in a Japanese cohort: the TOMORROW study

  RA (n = 177) Control (n = 183) p value Effect size
Women 151 (85) 154 (84) 0.77 0.02
Age (years) 61.0 (18.0) 60.0 (16.0) 0.64 0.02
Height (cm) 155.8 (10.4) 157.0 (10.7) 0.012 0.13
Weight (kg) 54.0 (13.3) 54.8 (12.7) 0.18 0.07
BMI (kg/m2) 22.1 (4.8) 22.3 (4.2) 0.82 0.01
Smoking 51 (29) 26 (14) 0.001 0.18
Drinking habits 78 (44) 94 (51) 0.17 0.07
RF (IU/ml) 43 (98) 8 (3) < 0.001 0.77
RF positive 134 (76) 20 (11) < 0.001 0.65
Anti-CCP (U/ml) 67.6 (86.3) 0.6 (0.2) < 0.001 0.81
Anti-CCP positive 152 (86) 5 (3) < 0.001 0.84
RA duration (years) 10.4 (15.5)
csDMARD user 162 (92)
bDMARD user 104 (59)
GC user 47 (27)
ESR (mm/h) 20 (25) 8 (8) < 0.001 0.41
MMP-3 (ng/ml) 64.5 (66.6) 43.0 (23.3) < 0.001 0.36
hs-CRP (mg/l) 0.11 (0.38) 0.03 (0.05) < 0.001 0.44
mHAQ-DI 0.25 (0.88)
TJC 2 (5)
SJC 0 (2)
Patient VAS 28 (40)
DAS28-ESR 3.4 (2.1)
  1. In age, height, weight, BMI, RF, anti-CCP, RA duration, ESR, MMP-3, hs-CRP, mHAQ-DI, TJC, SJC, patient VAS, and DAS28-ESR, data are shown as median (interquartile range) and other categorical data were shown as patient number (%). bDMARDs biological disease-modifying antirheumatic drugs, BMI body mass index, CCP anti-cyclic citrullinated peptide antibody, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, DAS28-ESR disease activity scores in 28 joints using erythrocyte sedimentation rates, E-DII energy-adjusted dietary inflammatory index, GC glucocorticoid, hs-CRP high-sensitivity C-reactive protein, mHAQ-DI modified health assessment questionnaire disability index, MMP matrix metalloproteinase, RA rheumatoid arthritis, RF rheumatoid factor, SJC swollen joint count, TJC tender joint count, VAS visual analog scale